{"id":17339,"date":"2021-06-18T10:09:24","date_gmt":"2021-06-18T08:09:24","guid":{"rendered":"https:\/\/www.izb-online.de\/prof-dr-ernst-wagner-wird-in-den-wissenschaftlichen-beirat-von-coriolis-pharma-berufen\/"},"modified":"2021-06-18T12:50:47","modified_gmt":"2021-06-18T10:50:47","slug":"prof-dr-ernst-wagner-wird-in-den-wissenschaftlichen-beirat-von-coriolis-pharma-berufen","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/prof-dr-ernst-wagner-appointed-to-the-scientific-advisory-board-of-coriolis-pharma\/","title":{"rendered":"Prof. Dr. Ernst Wagner appointed to the Scientific Advisory Board of Coriolis Pharma"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Prof. Dr. Ernst Wagner appointed to the Scientific Advisory Board of Coriolis Pharma<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]Expert in nucleic acids and gene delivery strengthens Coriolis’ scientific expertise[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]June 2021[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”17327″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Coriolis Pharma[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Prof. Ernst Wagner, member Scientific Advisory Board at Coriolis Pharma[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\u201cIt is a pleasure and honor for me to support Coriolis Pharma as company originating from the LMU, after having followed their scientifically driven great success during the last years.\u201d<\/h6>\n

Prof. Ernst Wagner
\nMember Scientific Advisory Board at Coriolis Pharma<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of (bio)pharmaceutical drugs, today announced that Prof. Dr. Ernst Wagner has joined its scientific advisory board. Prof. Wagner\u2019s distinguished expertise with nucleic acids and gene delivery perfectly fits to the services offered by Coriolis Pharma and strengthens Coriolis\u2019 scientific expertise in the field of advance therapy medicinal products (ATMPs).<\/p>\n

\u201cWe are very pleased to welcome Ernst to our scientific advisory board,\u201c said Dr. Michael Wiggenhorn, CEO of Coriolis Pharma. \u201cHis distinguished expertise about nucleic acids and gene delivery will be of high value to our client projects, particularly in the booming field of advanced therapy medicinal products. Ernst will actively be involved in project discussions and will contribute with his long-year experience to successful project outcomes.\u201d<\/p>\n

Prof. Wagner is a professor of Pharmaceutical Biotechnology at the Ludwig-Maximilians-Universit\u00e4t (LMU) and the Center of Nanoscience in Munich, Germany. Previously (1991-2001), he was the Director Cancer Vaccines & Gene Therapy at Boehringer Ingelheim in Vienna, Austria, where he supervised the first-in-world polymer-based human gene therapy trial in 1994. Prof. Wagner is an Academician of European Academy of Sciences, a member of the Controlled Release Society (CRS) College of Fellows, a board member of German Society for Gene Therapy, and the Editor-in-Chief of the Journal of Gene Medicine.<\/p>\n

Prof. Wagner has authored more than 475 publications with almost 45 000 citations. His current academic research projects focus on the targeted delivery of nucleic acids (including mRNA) and protein therapeutics.<\/p>\n

\u201cErnst\u2019s research interest also fits perfectly to the scope of our internal research unit,\u201d explains Dr. Andrea Hawe, CSO of Coriolis Pharma. \u201cWe are looking forward to collaborative research projects and joint publications in the exciting field of gene and cell therapy. This will be of direct benefit to our clients, because we always apply the gained knowledge from our research projects to improve the services for our clients.\u201d<\/p>\n

\u201cIt is a pleasure and honor for me to support Coriolis Pharma as company originating from the LMU, after having followed their scientifically driven great success during the last years,\u201d comments Prof. Wagner his move towards Coriolis.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote gco-magazine–quote-vertical-center” css=”.vc_custom_1624004460620{margin-top: 22px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\"Portrait-Dr.-Michael-Wiggenhorn\"
\n\u00a9 Coriolis Pharma<\/span><\/div>\n
\n
\u201cProf. Wagners distinguished expertise about nucleic acids and gene delivery will be of high value to our client projects, particularly in the booming field of advanced therapy medicinal productsn.\u201d<\/h6>\n

Dr. Michael Wiggenhorn CEO Coriolis Pharma<\/p>\n<\/div>\n

[\/vc_column_text][\/vc_column_inner][vc_column_inner][\/vc_column_inner][\/vc_row_inner][vc_empty_space height=”66px”]\n\n

\n \n \n
\n Coriolis Pharma <\/div>\n\n